Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis

Objective It is currently unknown how long GCA should be treated with tocilizumab. In the first randomized controlled trial, the biologic agent was stopped after 52 weeks. We therefore studied what proportion of patients relapsed, when relapses occurred and whether factors might predict relapse after tocilizumab treatment discontinuation. Methods All patients in the tocilizumab arm who had received a 52-week treatment were evaluated. In case of...